"Health wise I am feeling great. I am a big supporter of trials - it allows new treatments and drugs to be brought in.”
A trial looking at atrasentan for prostate cancer that has stopped responding to treatment and has not spread to another part of the body
We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.
This trial compared a new drug called atrasentan with a dummy drug (placebo) for men with prostate cancer that is no longer responding to hormone therapy.
Doctors often treat prostate cancer with hormone therapy. But sometimes this treatment can stop working and the cancer can continue to grow. This is called hormone refractory refractory prostate cancer. Doctors are always looking for new ways to improve treatment.
The aim of this trial was to see if a new drug called atrasentan could help to slow or stop prostate cancer growth. And to find out more about side effects.
Summary of results
The researchers found that atrasentan did not help to stop prostate cancer growing for the men in this trial. But many of the men stopped taking atrastentan earlier than they should have due to side effects. So that made it difficult for the research team to be sure how well it worked.
The trial recruited 941 men with prostate cancer
- Half had atrasentan
- Half had a dummy drug (a
The researchers analysed the results in 2007. They found the cancer had spread to another part of the body in 267 men who had the dummy drug and 227 men who had atrasentan. But this difference was no bigger than could have happened by chance (in other words, it was not ‘
The side effects reported by the men who had atrasentan included swollen arms and legs, a blocked nose, headaches, shortness of breath, a drop in red blood cells (anaemia) and heart problems. But most of the side effects were mild.
We have based this summary on information from the team who ran the trial. The information they sent us has been reviewed by independent specialists (
How to join a clinical trial
Dr David Dearnaley